Skip to main content

Prediction of ovarian function recovery in young breast cancer patients after protection with gonadotropin-releasing hormone agonist during chemotherapy

Abstract

Purpose

This study evaluated predictive factors for recovery of ovarian function after ovarian protection by GnRH agonist during chemotherapy in young breast cancer patients.

Methods

This prospective cohort study analyzed 105 young breast cancer patients who were studied longitudinally after receiving GnRH agonist during cyclophosphamide-based chemotherapy for ovarian protection. Associations between pretreatment hormones, clinical factors, and recovery of ovarian function (resumption of menstruation or anti-Müllerian hormone (AMH) ≥ 1 ng/ml) were evaluated at 12 months and long-term follow-up after completion of chemotherapy.

Results

Mean age was 32 years (range 23–42 years). In multivariate analyses, tamoxifen use (P = 0.035) and pretreatment follicle-stimulating hormone (FSH) (P = 0.032) were predictive of resumption of menstruation, and age (P = 0.019), tamoxifen use (P = 0.022), pretreatment FSH (P < 0.001), and AMH (P = 0.040) were predictors for AMH ≥ 1 ng/ml at 12 months. In addition, pretreatment AMH was a predictor for AMH ≥ 1 ng/ml after long-term follow-up. Receiver operating characteristic curve analyses gave area under the curve of 0.805 for resumption of menstruation and 0.903 for serum AMH concentration ≥ 1 ng/ml at 12 months, when age, tamoxifen use, pretreatment FSH, and AMH were combined.

Conclusion

Pretreatment AMH (3.26 ng/ml), age (33.9 years), pretreatment FSH (5.5 IU/l), and tamoxifen use are useful predictors for AMH ≥ 1 ng/ml at 12 months after GnRH agonist. This finding will support patient and clinician decision-making regarding fertility preservation.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2

References

  1. 1.

    Peto R et al (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379(9814):432–444

    Article  PubMed  CAS  Google Scholar 

  2. 2.

    Loren AW et al (2013) Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31(19):2500–2510

    Article  PubMed  PubMed Central  Google Scholar 

  3. 3.

    Anders CK et al (2008) Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 26(20):3324–3330

    Article  PubMed  Google Scholar 

  4. 4.

    Thomas-Teinturier C et al (2015) Ovarian reserve after treatment with alkylating agents during childhood. Hum Reprod 30(6):1437–1446

    Article  PubMed  CAS  Google Scholar 

  5. 5.

    Lee SJ et al (2006) American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 24(18):2917–2931

    Article  PubMed  Google Scholar 

  6. 6.

    Practice Committee of American Society for Reproductive Medicine (2013) Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. Fertil Steril 100(5):1214–1223

    Article  Google Scholar 

  7. 7.

    Del Mastro L et al (2011) Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA 306(3):269–276

    PubMed  Google Scholar 

  8. 8.

    Del Mastro L et al (2014) Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials. Cancer Treat Rev 40(5):675–683

    Article  PubMed  CAS  Google Scholar 

  9. 9.

    Blumenfeld Z, Zur H, Dann EJ (2015) Gonadotropin-Releasing Hormone Agonist Cotreatment During Chemotherapy May Increase Pregnancy Rate in Survivors. Oncologist 20(11):1283–1289

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. 10.

    Coates AS et al (2015) Tailoring therapies–improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 26(8):1533–1546

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. 11.

    Moore HC et al (2015) Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 372(10):923–932

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. 12.

    Lambertini M et al (2016) Cancer and fertility preservation: international recommendations from an expert meeting. BMC Med 14:1

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. 13.

    Leonard RCF et al (2017) GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial. Ann Oncol 28(8):1811–1816

    Article  PubMed  CAS  Google Scholar 

  14. 14.

    Nelson SM et al (2007) Serum anti-Müllerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles—implications for individualization of therapy. Hum Reprod 22(9):2414–2421

    Article  PubMed  CAS  Google Scholar 

  15. 15.

    Lambertini M et al (2015) Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. Ann Oncol 26(12):2408–2419

    PubMed  CAS  Google Scholar 

  16. 16.

    Badawy A, Elnashar A, El-Ashry M, Shahat M (2009) Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril 91(3):694–697

    Article  PubMed  CAS  Google Scholar 

  17. 17.

    Song G, Gao H, Yuan Z (2013) Effect of leuprolide acetate on ovarian function after cyclophosphamide-doxorubicin-based chemotherapy in premenopausal patients with breast cancer: results from a phase II randomized trial. Med Oncol 30(3):667

    Article  PubMed  CAS  Google Scholar 

  18. 18.

    Henry NL et al (2014) Prediction of postchemotherapy ovarian function using markers of ovarian reserve. Oncologist 19(1):68–74

    Article  PubMed  CAS  Google Scholar 

  19. 19.

    Anderson RA, Rosendahl M, Kelsey TW, Cameron DA (2013) Pretreatment anti-Mullerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer. Eur J Cancer 49(16):3404–3411

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  20. 20.

    Anderson RA et al (2006) The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod 21(10):2583–2592

    Article  PubMed  CAS  Google Scholar 

  21. 21.

    Anders C et al (2008) A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer. Cancer Invest 26(3):286–295

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  22. 22.

    Pagani O et al (1998) Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer 34(5):632–640

    Article  PubMed  CAS  Google Scholar 

  23. 23.

    Jeruss JS, Woodruff TK (2009) Preservation of fertility in patients with cancer. N Engl J Med 360(9):902–911

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  24. 24.

    Swain SM et al (2009) Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial. Breast Cancer Res Treat 113(2):315–320

    Article  PubMed  CAS  Google Scholar 

  25. 25.

    Anderson RA, Cameron DA (2011) Pretreatment serum anti-Mullerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. J Clin Endocrinol Metab 96(5):1336–1343

    Article  PubMed  CAS  Google Scholar 

  26. 26.

    Ruddy KJ et al (2014) Biomarker prediction of chemotherapy-related amenorrhea in premenopausal women with breast cancer participating in E5103. Breast Cancer Res Treat 144(3):591–597

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  27. 27.

    Partridge AH et al (2010) Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. Fertil Steril 94(2):638–644

    Article  PubMed  Google Scholar 

  28. 28.

    Yu B et al (2010) Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy. Cancer 116(9):2099–2105

    PubMed  PubMed Central  CAS  Google Scholar 

  29. 29.

    Han HS et al (2009) Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer. Breast Cancer Res Treat 115(2):335–342

    Article  PubMed  CAS  Google Scholar 

  30. 30.

    Petrek JA et al (2006) Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol 24(7):1045–1051

    Article  PubMed  Google Scholar 

  31. 31.

    Anderson RA et al (2017) The utility of anti-Müllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer. Eur J Cancer 87:58–64

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  32. 32.

    Dezellus A et al (2017) Prospective evaluation of serum anti-Müllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer. Eur J Cancer 79:72–80

    Article  PubMed  CAS  Google Scholar 

  33. 33.

    Shandley LM et al (2017) Impact of tamoxifen therapy on fertility in breast cancer survivors. Fertil Steril 107(1):243.e5–252.e5

    Article  CAS  Google Scholar 

  34. 34.

    Arriagada R et al (2005) Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy. Ann Oncol 16(3):389–396

    Article  PubMed  CAS  Google Scholar 

  35. 35.

    Pagani O et al (2014) Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 371(2):107–118

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  36. 36.

    Lambertini M et al (2015) Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: a randomized clinical trial. JAMA 314(24):2632–2640

    Article  PubMed  CAS  Google Scholar 

  37. 37.

    Larsen EC et al (2003) Reduced ovarian function in long-term survivors of radiation- and chemotherapy-treated childhood cancer. J Clin Endocrinol Metab 88(11):5307–5314

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors wish to gratefully acknowledge the biostatistics team of Samsung Biomedical Research Institute, Seoul, Korea for assistance in the preparation of this article.

Author information

Affiliations

Authors

Corresponding author

Correspondence to DooSeok Choi.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Lee, DY., Park, Y.H., Lee, J.E. et al. Prediction of ovarian function recovery in young breast cancer patients after protection with gonadotropin-releasing hormone agonist during chemotherapy. Breast Cancer Res Treat 171, 649–656 (2018). https://doi.org/10.1007/s10549-018-4863-2

Download citation

Keywords

  • Breast cancer
  • Chemotherapy
  • Ovarian protection
  • Gonadotropin-releasing hormone agonist